Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (Avastinâ„¢) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

The National Cancer Institute (NCI), part of the National Institutes of Health, has awarded $11 million to complete funding for the next five years of research from the Early Detection Research Network (EDRN). EDRN brings together dozens of institutions to help accelerate the translation of biomarker information into clinical application and to evaluate new ways […]

A pilot study of an experimental therapy for prostate cancer has found that a cancer vaccine can be safely administered to patients undergoing radiation therapy. In some patients receiving the vaccine, an immune response against tumor cells may occur, according to the results of a phase II clinical trial led by scientists at the National […]